- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Ian Neeland Describes Physiologic Effects of SGLT2 Inhibitors on Sleep Apnea
Ian J. Neeland, MD, FACC, FAHA, is co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute and director of the UH Center for Cardiovascular Prevention, in the Cleveland, Ohio, area. Here, he explains how sodium-glucose co-transporter 2 (SGLT2) inhibitors can treat metabolic physiologic effects of sleep apnea.
Transcript
It has been several years since the first studies showed GLP1-receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors can reduce cardiovascular events. What have we learned about the mechanisms of action of these drugs that makes them useful for multiple purposes?
There are many physiologic effects of SGLT2 inhibitors, both in the heart as well as the kidney. SGLT2 inhibition can improve glycemic control, high blood pressure–it can alter obesity or hypotoxicity, potentially inflammation, hypoxia, and fibrosis.
As we're learning more about these different effects of these medications, sleep deficiency, which is a metabolic problem often—not just related to an atomic dysfunction the way your anatomy is, [such as] thick neck or fat deposition of the neck that crowds out the airway—but also there's metabolic or non-anatomic physiologic traits of sleep apnea that SGLT2 inhibition actually might influence–these non-anatomic metabolic traits.
SGLT2 inhibition, in a sense, actually can attack both the anatomic problem–like the fat deposition, decrease the adiposity in the neck and in the gut—as well as potentially improve the metabolism in the patient to actually treat sleep deficiency from both ends.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
